syndrome and those that are regulated by androgens not only in granulosa cells but also in theca, stroma, and immune cells in the ovary.
In the ovarian cancer field, she has generated novel and very innovative mouse models that mimic human ovarian serous adenocarcinomas and granulosa cell tumors (GCTs). Using the ovarian surface epithelium-specific mutant mouse models, she is determining the interactions of the tumor-repressor protein p53 and steroid hormones to identify new mechanisms that can be targeted for therapeutic purposes to improve early detection and patient survival. Using GCT mouse models, her research group is exploring the changes in granulosa cell fate following depletion of key transcription factors, FOXO1 and FOXO3, and PTEN, a tumor suppressor.
Finally, Dr. Richards' novel observations indicate that cumulus cells surrounding mature oocytes acquire many characteristics of immune cells and express immune cell-related genes such as the toll-like receptors involved in surveillance mechanisms. Thus, she envisions that endocrine and immune-like functions are critical for normal ovarian cell function and likely also impact ovarian cancer progression.
Dr. Richards has received continuous funding form the NIH. She published 190 peer-reviewed research papers and about 20 classic and highly cited text book chapters and reviews. She received numerous prestigious awards for her outstanding research work and some of them include-the NIH Career Development Award (1978) (1979) (1980) (1981) (1982) (1983) , the SSR Research Award (1989) , the Endocrine Society Griff T. Ross Award (1990) , the British Endocrine Society Transatlantic Medal (1995) , Endocrine Society Gerald Aurbach Award (1998 ), Frontiers in Reproduction Pioneer Lecture Award (2003 , the Endocrine Society Women in Endocrinology Mentor Award (2007) Dr. Richards has served in many leadership roles in both the Endocrine Society and SSR and on various committees and the editorial boards of the society journals, Molecular Endocrinology and Biology of Reproduction, respectively. At both her institutions, Baylor College of Medicine and at the national level, she served on several committees, including, as a member on several NIH study section panels. Her dedicated service to mentoring trainees is often discussed. She has served as the Director of Graduate Studies, Department of Cell Biology at Baylor College of Medicine, since 1988. As a mentor, she trained about 20 Ph.D. students, and until now served as a member on 30 Ph.D. thesis committees of graduate students. Nearly, 30 postdoctoral fellows received training in her laboratory and have gone on to become leaders in various institutions and organizations across the world. Her laboratory has also hosted 10 visiting scientists, notable among them are Dr. Louis De Paolo, then at the UT Health Science Center, San Antonio, Texas, and currently, the chief of fertility and infertility branch, Eunice Kennedy Shriver NICHD, NIH, Dr. Joanne Fortune, Cornell University, Ithaca, New York, and Dr. Masayuki Shimada, Hiroshima University, Japan. This interviewer has known and interacted with Dr. Richards for nearly 25 years now. She agreed to do this interview for Biology of Reproduction.
What attracted you to biology research and when did you decide to focus your attention on studying ovarian physiology?
My exposure to, and interest in, research happened for me by default. I went to Oberlin College to major in French but ended up majoring in Biology. I went to graduate school to get a job; that is to be certified and trained to teach high school biology after completing a Master of Arts and Teaching (MAT) Program at Brown University. The course work was fine. Unfortunately, 30 min of practice teaching in a local public high school in Rhode Island made me realize that I have absolutely no disciplinary skills; hence teaching was not going to be my forte. It was painful. Fortunately, the MAT program required everyone to do research. For me, the research project was exciting and, believe it or not, it was focused on relating NAD-kinase enzyme activity to steroidogenesis and to the electron microscopic structure of cells, yes . . . .. in the ovary! Thus, began my first foray into research. I applied to, entered, and completed the Ph.D. graduate program in physiological chemistry at Brown University with a thesis on the ovary.
During a significant part of your distinguished research career, you focused on understanding mechanisms of gonadotropin signaling in granulosa cells. How did you first perceive and then successfully approach this problem?
My first exposure to gonadotropic hormone signaling came when I accepted a postdoctoral position at the University of Michigan in 1971. At that time, measuring hormones was undergoing an exponential quantitative revolution. Laborious bioassays, such as measuring the increase in uterine weight as a response to estradiol, were being replaced by a whole new technology known as radioimmunoassay! Radioactivity had become available to basic scientists post-WWII. Ways to conjugate I 125 to proteins and labeling steroids with 3 H were being developed. Gamma counters were filling major spaces in labs. Enormous computers (consuming entire buildings) were available to analyze huge stacks of cards, spitting out reams of data sheets. For the first time ever, reproductive endocrinologists could apply radio-immunoassays to accurately and quickly measure gonadotropic and steroid hormones in serum. This was almost like landing on the moon! Radio-immunoassays evolved into radio-receptor assays and for the first time, hormone receptors could be measured and visualized in specific cells in tissue samples. Not only did we find that levels of hormones in serum change but also that hormone receptors levels in cells change and were themselves hormonally regulated! For example, follicle-stimulating hormone (FSH) and estradiol induced the expression of the luteinizing hormone (LH) receptor in granulosa cells of preovulatory follicles. I was extremely lucky to be part of this amazing period in endocrine research. Measuring receptors was quickly coupled to analyzing signaling cascades downstream of receptor activation. For the gonadotropic hormones, the first prominent pathway to emerge was the adenylyl cyclase, cyclic 5 -adenosine monophosphate (cAMP), and cAMPdependent protein kinase cascade. This led eventually to our cloning of the type II cAMP regulatory subunit of protein kinase A.
Your stellar contributions to understanding ovarian signaling mechanisms are well recognized, richly rewarded, and created a major influence on numerous investigators all over the world. How have you focused your attention so successfully into this fundamental and fascinating single problem?
For me, understanding the ovary has been an inspiration and a lifelong mission. It is an amazing organ that coordinates the growth and ovulation of many follicles and does so by tightly regulating signaling cascades in the oocyte, granulosa cells, and theca cells. Signaling cascades also determine those less successful follicles that will undergo atresia. Each experiment and mutant mouse model has brought new questions to be answered and new approaches to acquire. Analyzing ovarian signaling mechanisms has been a rewarding detective game that I have loved to play and luckily, I have not had to play the game alone. I have been honored to have many partners in the lab who have also enjoyed being detectives. So, it has been the collective excitement of the lab and people in the lab that have also continued to inspire and energize me. I have also been blessed with wonderful collaborators worldwide, some of whom I have never met in person but who have contributed to our studies in significant ways. I have not done all these studies alone! You have been an integral part of contributing to the "golden era" of reproductive biology at Baylor College of Medicine. What was your experience like being in such an exciting phase and "history-making" research environment?
Coming to BCM was an amazing moment in my life and being here since 1981 has been a marvelous journey. When I arrived it was clear that everyone had to have a gene in their pocket if they were going to succeed. The expertise in molecular biology and cloning genes allowed my lab to make the first ovarian cDNA library and to clone various genes such as those encoding the regulatory subunit of type II cAMP-dependent protein kinase A, prostaglandin synthase 2, a disintegrin and metalloproteinase with thrombospondin motifs 1, and others. This was a major impact on our ability begin to understand the regulation of specific genes in specific cell types at distinct stages of follicular growth. cDNA libraries faded out rapidly with the appearance and application of PCR technologies and microarray and RNA-seq technologies. Along the way, it also became clear that having mutant mouse models was an essential dimension to modern molecular biology. Again, the expertise in the department assisted us to obtain and generate mutant mouse models related to ovarian biology. The microscopy core facility provided technology and expertise to image follicles, oocytes, and cells. The department was like a big family that kept everyone together and moving forward . . . There was no time to rest or even think about resting. It has all been fun! How did you come up with the idea of generating a triple mutant mouse that develops cancer of the ovarian surface epithelium?
This was not a linear or well-conceived process. It evolved from our studies on the hormonal regulation of ovulation. We and others determined that one major impact of the LH surge on preovulatory follicles leading to ovulation was mediated by the induction of the epidermal growth factor (EGF)-like factors (AREG, EREG, BTC) and that these factors activated the EGF receptors, RAS and ERK1/2 kinases in granulosa cells and cumulus cells leading to cumulus cell oocyte complex (COC) expansion. This process was essential for the release of COCs at the time of ovulation. We naively asked what would be the impact of activating RAS at earlier stages of follicular development. For this, we generated the Kras G12D (flox/flox Kras G12D ;Amhr2-Cre) mutant mice that expressed stable active KRAS in granulosa cells. To our surprise, follicular development was blocked: the proliferation and differentiation of granulosa cells ceased, leaving odd comet-shaped follicles devoid of oocytes. However, the levels of PTEN protein were elevated in granulosa cells of these arrested follicles. So, in another naïve way, we asked if we selectively depleted Pten in granulosa cells would we revert abnormal follicular growth to back to normal. The answer was "no." The abnormal follicles remained. But amazingly, the ovarian surface epithelium (OSE) was transformed indicating that expression of stable Kras G12D and depletion of Pten in OSE cells had occurred by Amhr2-cre expression in those cells. We now suddenly had a mouse model of ovarian cancer in our colony. This was not to be ignored. Because mutations in the tumor protein 53 (p53) were present in greater than 95% of ovarian cancer tissues, we next disrupted the expression of p53 to generate a tumor null for p53 and which we expected would lead to more rampant tumor growth and metastasis to the peritoneal cavity. To our surprise again, the loss of p53 in our Kras/Pten mutant OSE cells did not promote tumor growth; rather only tiny finger-like lesions appeared. This seemed completely against all known dogma! But was consistent in each mutant mouse. However, these small lesions responded dramatically to exogenous estrogen and large metastatic tumors appeared rapidly throughout the peritoneal cavity. Thus, because the ovaries of the Kras/Pten were devoid of healthy steroidogenic follicles, the p53 null tumors in these mice did not grow until exogenous estrogen was supplied. This amazing steroid-dependent tumor growth led us to conclude that the status of p53 (WT vs. null) and steroid hormones are critical for OSE metastatic activity. So how did we come up with a triple mutant mouse model? It was not by doing the perfect experiment but rather by exploring the amazing phenotype of mutant mice in which follicular development was arrested and in which the OSE cells were transformed. Subsequent studies have shown that specific gain-of-function p53 mutants also impact this model and responses to steroids.
Recently, you have turned your attention to androgen action in other nongranulosa cells within the ovary. You have also made interesting observations on Toll-like receptors and their roles in ovary. How did you transition into these very interesting problems?
We became keenly interested in androgen action in the ovary when a Clinical Scientist Training Program (CSTP) fellow in the OB/GYN department at BCM decided to do her research component in our lab. Granulosa cells were obtained from normal or polycystic ovarian syndrome (PCOS) patients undergoing IVF, RNA was extracted and analyzed by microarray and qPCR and the data stratified based on BMI, androgen, and cytokine levels in these women. Remarkably, expression of local inflammatory molecules was elevated in granulosa cells of obese PCOS patients compared to nonobese PCOS patients. Because hyperandrogenemia as well as a pro-inflammatory state are cardinal signs of PCOS, we began thinking about theca cells, androgens, and follicle development and decided to treat mice with exogenous androgens to mimic a PCOS-like environment. This model intrigued us and clearly led to abnormal follicle growth and the expression of specific genes, some of which appeared to be preferentially elevated in the ovarian stroma compared to granulosa cells. The real impetus to consider theca cells per se came from reading a seminal paper from Sheng Wu lab in which they documented that disrupting the androgen receptor (AR) selectively in theca cells blocked the PCOS-like effects of exogenous androgens in their mice. Dr. Wu generously sent some of her precious RNA for us to test the expression of some genes we had identified in our mouse models. This was the beginning of our androgen-theca cell study, the identification of vascular cell adhesion molecule 1 (VCAM1) as a possible androgen regulated gene and our current interest in the interactions of AR, NR2F2 (COUPTF-II), and VCAM1 in theca cells of mice and in normal and PCOS patients (a collaboration with Jan McAllister). The Toll-receptor story began when we ran microarrays on COCs isolated at various times from follicles of preovulatory follicles prior to ovulation and that lipopolysaccharide could induce some of these genes.
Is there any particular research problem in granulosa cell biology that you are going after and still remains a mystery to you all these years?
I am still wondering why granulosa cells in the Kras/Pten mice undergo growth arrest, whereas OSE cells are transformed by these same two oncogenic factors. And what are the mechanisms controlling growth arrest but not differentiation or apoptosis in these granulosa cells. This intrigues me. I would also like to know how primordial follicles are formed and what factors are essential for the attachment and recruitment of progenitor granulosa cells to the oocytes and how this may impact the loss of oocytes in the developing mammalian ovary. I am also curious about the reversibility of granulosa cells to a Sertoli-like or epithelial-like phenotype expressing SOX9 as observed in our Foxo/Pten knockout tumor cells. Can granulosa cells revert to an epithelial-like cell expressing SOX9 and KRT8?
How have you been successfully managing for the past 30 years as the director of graduate studies in molecular and cellular biology at Baylor College of Medicine and training numerous graduate students and postdoctoral fellows?
Being director of the graduate program in the molecular and cellular biology department has been a highly rewarding experience. I enjoy students, I like to see them mature and I am thrilled when they graduate. Their transition during graduate school is always remarkable, and it has kept me young in spirit. I have also had amazing program administrators who have made "managing" easy for me by taking care of many details, recruiting efforts and assisting students with courses, selecting mentors and day-to-day issues. Having young people in the lab is energizing and fun, even if sometimes challenging. I have enjoyed having them as part of the "family." We have all learned from each other, enjoyed the ups and survived the downs of research together and kept on searching to understand the secrets of the ovary or other exciting biological systems, such as bone!
What is your advice to our young generation of scientists interested in pursuing a career in reproductive biology?
Welcome aboard and have a good journey!! I believe that reproductive biologists are a special "breed" of scientists who thoroughly enjoy what they are doing and the people around them. There is never a dull moment when one is trying to make the world of reproduction healthier and safer for everyone and all species. New discoveries in the future will make our lives even better. I see improvements in IVF, new approaches to preserving oocytes or germ cell stem cells, greater understanding of PCOS and premature ovarian failure and new insights into aging. On a more practical level, as a young scientist, it is important to read, be critical, be collaborative, and find a mentor and project area that really stimulates you. Research is a rather masochistic sport, so resilience and perseverance are also the keys to success. Focus on good ideas, be courageous, and do not worry about an occasional stumble. It happens to all of us. Seek advice! If experiments are not working, and if the issue is not technical, then pay attention. There may be something important to learn. As an example, when we were trying to clone the cyclooxygenase gene, we made several antibodies in rabbits against purified sheep seminal vesicle cyclooxygenase protein. We obtained one antibody that documented striking induction of an ovarian protein on western blots following hCG administration to eCG-primed mice. A time course indicated that it was clearly associated with the ovulation process and supported biochemical data that ovulation was associated with prostaglandin production and inflammation. However, when screening our cDNA library, we never obtained a positive clone. The rabbit producing the antibody died so we had to start over! When analyzing the new antibodies by western blots, we found that sometimes we saw induction of a protein of the correct size and, sometimes not? Why was this? It turned out that only one of the antibodies recognized an induced protein, the other antibodies recognized a protein of quite similar size but was constitutively expressed at lower levels. These results were exciting because they indicated that there might be two forms of cyclooxygenase, not just one, maybe two genes: one inducible, one not!! We were off and running. We purified the induced protein, got amino acid sequence, and could confirm that indeed there were two proteins and eventually we confirmed two mRNAs using cDNAs. The induced form is now known as COX2 (PTGS2) and the noninduced as COX1(PTGS1). This took time to resolve but ultimately the discovery was rewarding and one of the most memorable in the early days of screening the cDNA library.
Where do you envision reproductive biology research is heading to in the coming years?
Many factors impact reproductive success, not only hormones but also environmental toxins that impact the reproductive tissues. Thus, hormones, hormonal signaling, and environmental factors will remain key issues for reproductive biology. In this regard, we need to protect the endangered species in the world as well as manage wildlife numbers through fertility measures. We need to know more about cell-cell interactions and what activates primordial follicles. We hear more and more about the importance of the immune system and inflammation, metabolism, and obesity. Because obesity is associated with inflammation and metabolism and has become a world health crisis, we need to eliminate fructose from the world diet and soft drinks (like the ban on cigarettes) and find better ways to control or eliminate this disease and improve reproductive success. Improvements for IVF and pregnancy outcomes will no doubt emerge. New evidence for ovarian germ cell stem cells needs to be confirmed and used to provide ways to preserve these cells for fertility in women undergoing cancer radiation treatment. We need to unveil new factors allowing us to override infertility in women with POF and PCOS as well as factors controlling infertility in men. Aging has become a recent focus for reproductive health because modern medicine is improving and extending our life expectancy. No doubt we will learn more about the hierarchical regulation of genes, RNAs, and the processing of RNA that are critical for maintaining oocyte development and quality as well as follicular growth and regulation of other endocrine processes. Lastly, I hope that we will be able to find better ways to manage or eradicate cancers in reproductive tissues in women and men. Having worked on a mouse model of ovarian cancer, I have come to understand and appreciate how devious and immortal some cancer cells are, how hormones can impact these cells, and how much smarter we need to be to control cancer growth and metastasis.
